GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-240-6320740
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
GenVec (NASDAQ:GNVC) Frequently Asked Questions
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
GenVec shares reverse split before market open on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
How were GenVec's earnings last quarter?
GenVec Inc (NASDAQ:GNVC) issued its quarterly earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million. View GenVec's Earnings History.
Has GenVec been receiving favorable news coverage?
Press coverage about GNVC stock has trended positive on Wednesday, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GenVec earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are GenVec's key executives?
GenVec's management team includes the folowing people:
- Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
- Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
- William N. Kelley M.D., Independent Director
- Stefan D. Loren Ph.D., Independent Director
- Quinterol J. Mallette M.D., Independent Director
- Michael S. Richman, Independent Director
- Marc R. Schneebaum, Independent Director
How do I buy shares of GenVec?
Shares of GNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenVec's official website?
How can I contact GenVec?
GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.
MarketBeat Community Rating for GenVec (NASDAQ GNVC)
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe GNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
